WHO ICTRP trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of…
PER-027-17 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-027-17 |
|---|---|
| Public title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk |
| Scientific title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | IV |
| Countries | Israel;Japan;Bulgaria;Slovakia;Russian Federation;Ukraine;South Africa;Argentina;Chile;Colombia;Mexico;Peru;United States |
| Conditions | -E780 Pure hypercholesterolaemia Cholera Pure hypercholesterolaemia;A00 ;E780;Cholera;Pure hypercholesterolaemia |
| Interventions | Dose/Route/Schedule: 75 mg /subcutaneous (SC)/Q2W for 94 weeks* * If LDL-C is ≥50 mg/dL (1.3 mmol/L) at week 8, Praluent dose will be increased to 150 mg Q2W at week 12. Placebo: Placebo matching Praluent Dose/Route/Schedule: SC/Q2W for 94… |
| Registration date | Feb 10, 2017 |
| Target size | 23 |
| Secondary IDs | NCT02957682;2016-003189-16 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: